Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current best practice in the evaluation and management of malignant pleural effusions.

Therapeutic advances in respiratory disease - 1 Feb 2017

Walker Steven, Bibby Anna C, Maskell Nick A

Abstract excerpt

Malignant pleural effusions (MPEs) are an important cause of cancer-related mortality and morbidity. It is a heterogeneous group of conditions, which leads to debilitating symptoms and confers a poor prognosis. Recent well-designed randomized trials have provided a broader evidence base for an expanding range of treatment options. Together, with new prognostic scoring systems and a greater understanding of how...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Phenotype
Share to Pleural Effusion, Malignant
Share to Precision Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Randomized Controlled Trials as Topic

Share to Research Design

Source

Open in PubMed Open full text

Identifiers

PMID: 27777372
DOI: 10.1177/1753465816671697
PMCID: PMC5933635

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current best practice in the evaluation and management of malignant pleural effusions.PMID 27777372Read ↗

Phenotyping malignant pleural effusions.Semantic proximity Read ↗

Diagnostic molecular biomarkers for malignant pleural effusions.Semantic proximity Read ↗

Clinical identification of malignant pleural effusionsSemantic proximity Read ↗

Management of malignant pleural mesothelioma.Semantic proximity Read ↗

Diagnosis and Treatment of Pleural EffusionSemantic proximity Read ↗

Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).Semantic proximity Read ↗

Pleural effusion in lung cancer: more questions than answers.Semantic proximity Read ↗

Lung adenocarcinoma with malignant serous effusions: A comprehensive clinicopathologic, molecular, and outcome analysis.Semantic proximity Read ↗

Patient-derived organoids from malignant pleural effusion to explore for alternative therapies in thoracic tumorsSemantic proximity Read ↗

Clinical and Molecular Features of Malignant Pleural Effusion in Non-Small Cell Lung Cancer (NSCLC) of a Caucasian Population.Semantic proximity Read ↗

[Malignant pleural mesothelioma: 2013 state of the art].Semantic proximity Read ↗

Survival of lung adenocarcinoma patients with malignant pleural effusion.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.